Drugs for acid-related disorders

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

Retrieved on: 
Tuesday, April 26, 2022
Goldman Sachs, Board, Vonoprazan, EXEL, MBA, Twitter, Degenerative disease, Roivant Sciences, Board of directors, Drugs for acid-related disorders, Organization, GLOBE, Exelixis, LinkedIn, WHU – Otto Beisheim School of Management, Nasdaq, Company, NYSE, Pharmaceutical industry, Management

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors.

Key Points: 
  • FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors.
  • We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom, said Terrie Curran, President and Chief Executive Officer of Phathom.
  • Mr. Karbe has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc. Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Friday, April 1, 2022
Company, LinkedIn, News, Vonoprazan, Conference, Drugs for acid-related disorders, Baozou Big News Events, Twitter, Nasdaq, GLOBE, Degenerative disease, Pharmaceutical industry

Company management will also participate in one-on-one meetings during the virtual conference which runs from April 11-14, 2022.

Key Points: 
  • Company management will also participate in one-on-one meetings during the virtual conference which runs from April 11-14, 2022.
  • To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations .
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • For more information about Phathom, visit the Companys website at http://www.phathompharma.com and follow the Company on LinkedIn and Twitter .

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

Retrieved on: 
Tuesday, March 22, 2022
Company, Chief business officer, LinkedIn, Organization, Board, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, State university system, Advaxis, Urologic disease, Vonoprazan, Chief financial officer, Drugs for acid-related disorders, Buffalo, Senior, Industry, Director, Twitter, MS, Nasdaq, MBA, GLOBE, Degenerative disease, Audit committee, Pharmaceutical industry, Management

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.

Key Points: 
  • FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.
  • Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (Nasdaq: URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease.
  • Molly brings to Phathom deep financialacumenand significant industry experience across mid-size and large-scalecommercialorganizations, and we are excited to have her join our executive leadership team, said Terrie Curran, President and Chief Executive Officer of Phathom.
  • She was previously the Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Ms. Henderson holds an MBA and MS in Accounting from the State University of New York at Buffalo.

Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis

Retrieved on: 
Monday, March 14, 2022
Esophagus, Nasdaq, Safety, Stomach, Lansoprazole, Twitter, Maintenance, Private Securities Litigation Reform Act, Mortality, Company, Marketing, Research, Helicobacter pylori, U.S. Securities and Exchange Commission, FDA, Gastroesophageal reflux disease, Chest pain, Acid erosion, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, PPI, Angina, QIDP, NDA, Vonoprazan, GLOBE, Amoxicillin, Clarithromycin, Drugs for acid-related disorders, Patient, Security (finance), NDAS, GERD, Standard of care, Heartburn, Degenerative disease, Esophagitis, EE, SEC, Food, Goal, Fast Track, LinkedIn, Pharmaceutical industry, Takeda, NERD

Erosive esophagitis, a major type of gastroesophageal reflux disease (GERD), affects approximately 20 million people in the U.S.

Key Points: 
  • Erosive esophagitis, a major type of gastroesophageal reflux disease (GERD), affects approximately 20 million people in the U.S.
  • We believe there is great interest among patients and healthcare providers for new treatment options to address the shortcomings of current treatment.
  • If approved, vonoprazan has the potential to satisfy the large unmet needs of millions of patients and set a new treatment paradigm in EE.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress

Retrieved on: 
Tuesday, March 1, 2022
Private Securities Litigation Reform Act, NDA, EE, Social media, Infection, Helicobacter pylori, Research, Food and Drug Administration, Heartburn, Amoxicillin, Food, Security (finance), U.S. Securities and Exchange Commission, Vonoprazan, QIDP, FDA, New Drug Application, Goal, Fast Track, Company, SEC, NDAS, Clarithromycin, Marketing, Esophagitis, Maintenance, Degenerative disease, Clinical trial, Drugs for acid-related disorders, GERD, Nasdaq, GLOBE, Stomach, Gastroesophageal reflux disease, Pharmaceutical industry, Lithium, Aquaculture, NERD, Takeda

Full Year 2021 and Recent Business Highlights:

Key Points: 
  • Full Year 2021 and Recent Business Highlights:
    Positive topline results in pivotal Phase 3 trial for vonoprazan-based therapies in treatment H. pylori infection (PHALCON-HP).
  • Fourth Quarter and Full Year 2021 Financial Results:
    Fourth quarter net loss for 2021 was $35.8 million, compared to $53.7 million for fourth quarter 2020.
  • Fourth quarter 2021 general and administrative expenses increased to $19.5 million compared to $10.8 million for fourth quarter 2020 primarily due to the ongoing buildout of the commercial function in 2021.
  • Phathom submitted new drug applications in September 2021 to the FDA for vonoprazan-based regimens for the treatment of H. pylori infection.

Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 23, 2021
Degenerative disease, Baozou Big News Events, Conference, Company, News, EST, Nasdaq, Twitter, GLOBE, Drugs for acid-related disorders, LinkedIn, Vonoprazan, Pharmaceutical industry

FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate virtually in the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021 at 9:15 a.m. EST.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate virtually in the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021 at 9:15 a.m. EST.
  • Members of Phathoms management team will also participate in one-on-one meetings throughout the conference which runs from November 30 December 2, 2021.
  • To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations .
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences

Retrieved on: 
Friday, November 12, 2021
News, Baozou Big News Events, Drugs for acid-related disorders, Degenerative disease, Twitter, Nasdaq, GLOBE, Vonoprazan, LinkedIn, Pharmaceutical industry

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate at two upcoming virtual investor conferences, including:

Key Points: 
  • FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate at two upcoming virtual investor conferences, including:
    Members of Phathoms management team will also participate virtually in one-on-one meetings throughout the duration of each conference.
  • To access the live webcast and archived recording of the presentations, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations .
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • For more information about Phathom, visit the Companys website at www.phathompharma.com and follow the Companyon LinkedIn and Twitter .

Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

Retrieved on: 
Monday, November 8, 2021
NDA, Safety, Maintenance, Degenerative disease, Business, NDAS, Priority review, Gastroesophageal reflux disease, GERD, Private Securities Litigation Reform Act, Loan agreement, Clinical trial, Security (finance), Helicobacter pylori, EE, Drugs for acid-related disorders, Loan, Food, Research, Amoxicillin, QIDP, File, Twitter, Stomach, Prescription Drug User Fee Act, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, GLOBE, LinkedIn, SEC, PDUFA, Vonoprazan, Heartburn, Clarithromycin, Fast Track, Patient, FDA, Marketing, Pharmaceutical industry, Lithium

If approved, the U.S. commercial launch for vonoprazan dual and triple therapy is anticipated in the second half of 2022.

Key Points: 
  • If approved, the U.S. commercial launch for vonoprazan dual and triple therapy is anticipated in the second half of 2022.
  • Recent Business and Financial Updates:
    On September 17, 2021, Phathom secured an up to $200 million term loan facility from Hercules Capital (Loan Agreement).
  • Third Quarter 2021 Financial Results:
    Third quarter 2021 net loss was $36.7 million compared to $34.1 million for the third quarter of 2020.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

Phathom Pharmaceuticals Withdraws Public Offering

Retrieved on: 
Thursday, October 28, 2021
Mission statement, Vonoprazan, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, SEC, Nasdaq, GLOBE, Degenerative disease, Drugs for acid-related disorders, Pharmaceutical industry

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases,announced today the withdrawal of the previously announced, proposed primary and secondary public offering.

Key Points: 
  • FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases,announced today the withdrawal of the previously announced, proposed primary and secondary public offering.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved.

Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock

Retrieved on: 
Tuesday, October 26, 2021
Takeda Pharmaceutical Company, Research, Takeda, Vonoprazan, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Telephone, Needham & Company, Equity capital markets, SEC, Guggenheim Partners, Floor, Madison Avenue, LLC, Company, Jefferies Group, Attention, Nasdaq, Prospectus, BMO Capital Markets, GLOBE, Sale, Degenerative disease, Drugs for acid-related disorders

FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public offering of 5,000,000 shares of its common stock (of which 4,000,000 shares of common stock are being offered by Phathom and 1,000,000 shares of common stock are being offered by Takeda Pharmaceutical Company Limited).

Key Points: 
  • FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public offering of 5,000,000 shares of its common stock (of which 4,000,000 shares of common stock are being offered by Phathom and 1,000,000 shares of common stock are being offered by Takeda Pharmaceutical Company Limited).
  • In addition, Phathom expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock and Takeda expects to grant the underwriters an option to purchase up to an additional 150,000 shares of common stock, in each case exercisable within 30 days.
  • Phathom will not receive any proceeds from the sale of common stock in this offering by Takeda.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.